SCHEMBL6287512

SCHEMBL6287512

CS(=O)(=O)N(CC1CCCNC1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
GPR88 Q9GZN0 1/20 0.44
MEN1 O00255 1/20 0.40
CHRNB2 P17787 3/20 0.40
CHRNA4 P43681 3/20 0.40
CHRNB4 P30926 2/20 0.40
CHRNA3 P32297 2/20 0.40
SLC6A2 P23975 4/20 0.40
SLC6A4 P31645 4/20 0.40
SLC6A3 Q01959 3/20 0.40
CYP2D6 P10635 2/20 0.39
USP30 Q70CQ3 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
PTGES O14684 1/20 0.38
ALOX5 P09917 1/20 0.38
EED O75530 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ACP1 P24666 1/20 0.38
KAT5 Q92993 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7801073 0.82 GBA1 (0.42) KMT2AMEN1SLC6A2SLC6A4SLC6A3
SCHEMBL6290202 0.79 HTR6 (0.42) KMT2AGPR88MEN1CHRNB2CHRNA4
SCHEMBL16837 0.77 LTA4H (0.39) KMT2AMEN1SLC6A2SLC6A4SLC6A3
SCHEMBL6290827 0.74 MAPT (0.55) KMT2AMEN1CYP2D6LMNAGAA
SCHEMBL21456816 0.74 KMT2A (0.43) KMT2AGPR88MEN1CHRNB2CHRNA4
SCHEMBL7567800 0.74 GPR88 (0.55) KMT2AGPR88CHRNB2CHRNA4CHRNB4
SCHEMBL21664326 0.73 APLNR (0.38) KMT2AGPR88SLC6A2SLC6A4SLC6A3
SCHEMBL12090185 0.71 POLB (0.52) KMT2AMEN1CYP2D6NPSR1
SCHEMBL12473957 0.71 CA1 (0.43) KMT2AMEN1LMNAGAA
SCHEMBL10795612 0.71 KMT2A (0.51) KMT2ACHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6872716-B2 Antipsychotic sulfonamide-heterocycles, and methods of use thereof SEPRACOR, INC. (US) 2005-03-29 US disclosed
US-20040235832-A1 ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF WU XINHE (US) 2004-11-25 US disclosed
US-6703383-B2 HETEROCYCLIC COMPOUNDS COMPRISING A SULFONAMIDE GROUP TO TREAT DISEASES SUCH AS PSYCHOLOGICAL DISORDERS CAUSED BY ONE OR MORE PROTEIN-G COUPLED RECEPTORS OR LIGAND -GATED ION CHANNELS SEPRACOR, INC. 2004-03-09 US disclosed
US-20020065265-A1 Antipsychotic sulfonamide-heterocycles, and methods of use thereof SEPRACOR INC. 2002-05-30 US disclosed
WO-2002022579-A2 ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF SEPRACOR, INC. (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065265-A1 Antipsychotic sulfonamide-heterocycles, and methods of use thereof TRPV1, CNR2, TRPM5 KMT2A 1488/4885GPR88 113/4885MEN1 4225/4885
US-20040235832-A1 ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF TRPV1, CNR2, TRPM5 KMT2A 1488/4885GPR88 113/4885MEN1 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.